EndoPredict
Device Tumor Dna Genetic Oncology Analysis
General payments
$43,670
Research payments
$588,284
Through program year 2022, $43,670 in general payments and $588,284 in research payments were reported against EndoPredict (Tumor Dna Genetic Oncology Analysis).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $8,507 | 14 |
| 2022 | Research | $207,900 | 60 |
| 2021 | General | $35,163 | 89 |
| 2021 | Research | $380,384 | 67 |
Breakdown
The top 5 of 9 recipients; each share is of general payments naming this product in 2022.
The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2022 where a state was reported.
Records
103 general · 127 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.